The EFSA NDA Panel evaluated whether maternal choline intake contributes to normal liver function of the fetus and breastfed infants, assessing the claim under EU Regulation (EC) No 1924/2006.
EFSA Journal · 17 authors
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
The EFSA NDA Panel evaluated whether maternal choline intake contributes to normal liver function of the fetus and breastfed infants, assessing the claim under EU Regulation (EC) No 1924/2006.
This EFSA scientific opinion evaluated a health claim application under Article 14 of Regulation (EC) No 1924/2006, concerning choline and contribution to normal fetal and infant development, especially of the liver. The Panel concluded that choline is sufficiently characterised, that contribution to normal liver function is beneficial for fetal and infant development and health, and that a cause and effect relationship has been established between maternal choline intake during pregnancy and lactation and normal liver function of the fetus and exclusively breastfed infants. The opinion does not constitute marketing authorisation or a safety assessment of choline.